P G Barnett1, J H Rodgers, D A Bloch. 1. Cooperative Studies Program and Health Economics Resource Center, VA Palo Alto Health Care System, US Department of Veterans Affairs, Menlo Park, CA 94025, USA. paul.barnett@med.va.gov
Abstract
BACKGROUND: The unique pharmacological properties of buprenorphine may make it a useful maintenance therapy for opiate addiction. This meta-analysis considers the effectiveness of buprenorphine relative to methadone. METHODS: A systematic literature search identified five randomized clinical trials comparing buprenorphine to methadone. Data from these trials were obtained. Retention in treatment was analyzed with a Cox proportional hazards regression. Urinalyses for opiates were studied with analysis of variance and a common method of handling missing values. A meta-analysis was used to combine these results. RESULTS: Subjects who received 8-12 mg/day buprenorphine had 1.26 times the relative risk of discontinuing treatment (95% confidence interval 1.01-1.57) and 8.3% more positive urinalyses (95% confidence interval 2.7-14%) than subjects receiving 50-80 mg/day methadone. Buprenophrine was more effective than 20-35 mg/day methadone. There was substantial variation in outcomes in the different trials. CONCLUSIONS: The variation between trials may be due to differences in dose levels, patient exclusion criteria and provision of psychosocial treatment. The difference in the effectiveness of buprenorphine and methadone may be statistically significant, but the differences are small compared to the wide variance in outcomes achieved in different methadone treatment programs. Further research is needed to determine if buprenorphine treatment is more effective than methadone in particular settings or in particular subgroups of patients.
BACKGROUND: The unique pharmacological properties of buprenorphine may make it a useful maintenance therapy for opiate addiction. This meta-analysis considers the effectiveness of buprenorphine relative to methadone. METHODS: A systematic literature search identified five randomized clinical trials comparing buprenorphine to methadone. Data from these trials were obtained. Retention in treatment was analyzed with a Cox proportional hazards regression. Urinalyses for opiates were studied with analysis of variance and a common method of handling missing values. A meta-analysis was used to combine these results. RESULTS: Subjects who received 8-12 mg/day buprenorphine had 1.26 times the relative risk of discontinuing treatment (95% confidence interval 1.01-1.57) and 8.3% more positive urinalyses (95% confidence interval 2.7-14%) than subjects receiving 50-80 mg/day methadone. Buprenophrine was more effective than 20-35 mg/day methadone. There was substantial variation in outcomes in the different trials. CONCLUSIONS: The variation between trials may be due to differences in dose levels, patient exclusion criteria and provision of psychosocial treatment. The difference in the effectiveness of buprenorphine and methadone may be statistically significant, but the differences are small compared to the wide variance in outcomes achieved in different methadone treatment programs. Further research is needed to determine if buprenorphine treatment is more effective than methadone in particular settings or in particular subgroups of patients.
Authors: Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice Journal: Drug Alcohol Depend Date: 2013-09-27 Impact factor: 4.492
Authors: Dennis W Raisch; Heather M Campbell; David A Garnand; Mark A Jones; Mike R Sather; Rupali Naik; Walter Ling Journal: Qual Life Res Date: 2011-10-11 Impact factor: 4.147
Authors: Anne M Neumann; Richard D Blondell; Urmo Jaanimägi; Amanda K Giambrone; Gregory G Homish; Jacqueline R Lozano; Urszula Kowalik; Mohammadreza Azadfard Journal: J Addict Dis Date: 2013